 The FDA has approved BeiGene Ltd NASDAQ: BGNE Brukinsa zanubrutinib for the treatment of adult patients with Waldenströms macroglobulinemia WM. Brukinsa WM approval is the second therapy approved specifically for the treatment of this rare type of lymphoma. 